NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
LODINE XL (etodolac) by Pfizer is clinical pharmacology pharmacodynamics etodolac is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. First approved in 1996.
Drug data last refreshed 3d ago
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of etodolac, like that of other NSAIDs, is not completely understood, but may be related…
Worked on LODINE XL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.